FeesSafety
Pluang+

Cabaletta Bio valued below cash, faces delay and risk in autoimmune drug trial

Analyst Insights
16 Nov 2026, 18:09 WIB
Seeking Alpha
View Source
Neutral
Cabaletta Bio valued below cash, faces delay and risk in autoimmune drug trial

Cabaletta Bio is valued at $276 million, less than its $299 million cash reserve, indicating low market value for its drug candidate rese-cel. The drug shows promising autoimmune responses but its key trial for dermatomyositis is delayed to late 2027, with a regulatory submission planned for 2028. The company’s cash is expected to last until early 2028, making further funding rounds likely. There is a significant risk that a single adverse event in the trial could halt progress and cause a major stock price drop.

Cabaletta Bio's valuation and trial delays provide context for readers. For those following health-sector stocks, here is Pluang's market snapshot as of Nov 16, 2026 22:13 WIB: Among 150 priced US health stocks, 70 rose and 79 fell. Notably, RXRX traded at USD 3.01 with a 5.49% decline, BFLY at USD 5.75 down 5.43%, and NTRA at USD 302.24 dropping 5.28%. Typical hold times on Pluang range from 10 to 23 days for these assets.

More News

MLCommons releases MLPerf Training v6.1 with new AI benchmarks and record participation.

MLCommons releases MLPerf Training v6.1 with new AI benchmarks and record participation.

MLCommons announced the MLPerf Training v6.1 benchmark results, introducing two new benchmarks focused on recommender systems and large-scale post-training for AI. This release highlights advances in AI training architectures and a growing diversity ...

Market News
Bullish
56 minutes ago
Hot-dip galvanized steel market for data centers to grow 12% CAGR, reaching $7.77B by 2036 driven by AI infrastructure demand.

Hot-dip galvanized steel market for data centers to grow 12% CAGR, reaching $7.77B by 2036 driven by AI infrastructure demand.

The global hot-dip galvanized steel market for data centers, valued at $2.05 billion in 2025, is projected to grow at a 12% CAGR to $7.77 billion by 2036. Growth is fueled by rapid AI data center construction, increasing power and cooling needs, and ...

Bullish
56 minutes ago
The Hospitality Show in Miami sees 48% rise in hotel buyers and 10% more exhibitors in 2026 event.

The Hospitality Show in Miami sees 48% rise in hotel buyers and 10% more exhibitors in 2026 event.

The Hospitality Show held in Miami from November 2-4, 2026, attracted thousands of hotel industry professionals, with a 48% increase in qualified hotel buyers and a 10% rise in exhibitors compared to the previous year. The event focused on connecting...

Market News
Bullish
56 minutes ago
Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

Anti-obesity drug market to hit $64.96B by 2035, led by Eli Lilly and Novo Nordisk with strong new drug launches.

The global anti-obesity drugs market is projected to grow from USD 8.96 billion in 2026 to USD 64.96 billion by 2035, driven by a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate the market with blockbuster drugs like Mounjaro, Zepbound, and Wegov...

Bullish
1 hour ago
Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

Walk assist robot market to grow 15% CAGR by 2031, driven by AI, aging population, and stroke rehab demand

The global walk assist robot market is projected to grow at a 15.01% CAGR from 2024 to 2031, fueled by advances in AI, machine learning, and hybrid wearable technology. Rising stroke incidence and an aging population are increasing demand for these r...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App